期刊文献+

哮喘患儿外周血半胱氨酰白三烯水平及5-脂氧合酶激活蛋白mRNA基因表达水平及其临床意义 被引量:4

Peripheral blood levels of cysteinyl leukotrienes and 5-lipoxygenase activating protein mRNA and their clinical significance in children with asthma
下载PDF
导出
摘要 目的探讨哮喘患儿外周血半胱氨酰白三烯(Cys LTs)水平及5-脂氧合酶激活蛋白(FLAP)mRNA基因表达水平及其临床意义。方法哮喘患儿(5岁及以下)40例,按病情等级划分轻、中、重、危重组,另外选取10名健康儿童作对照组。哮喘患儿随机分为常规治疗组及白三烯(LTs)拮抗剂干预组,每组20例。分别于入院24 h内、治疗第10天、3个月、1年、2年抽取外周血测定Cys LTs水平及FLAP mRNA/β-action mRNA的相对数值,并记录患儿病情等级和疗效情况。结果哮喘患儿的入院时Cys LTs水平及FLAP mRNA/β-action mRNA的相对数值均高于对照组(P<0.05),Cys LTs水平及FLAP mRNA/β-action mRNA与病情程度呈正相关性(P<0.05)。治疗第10天、3个月、1年及2年,LTs拮抗剂干预组的病情分级均轻于常规治疗组,但差异无统计学意义(P>0.05),疗效均优于常规治疗组(P<0.05);在治疗后各观察时间点,LTs拮抗剂干预组Cys LTs水平及FLAP mRNA/β-action mRNA的相对数值均显著低于常规治疗组(P<0.05)。结论 Cys LTs及FLAP mRNA水平与哮喘的病情呈正相关性,Cys LTs可能成为研究哮喘发病和药物治疗的重要指标;采用LTs拮抗剂联合ICS治疗患儿哮喘具有协同作用,有效控制Cys LTs及FLAP mRNA水平。 Objective To investigate the peripheral blood levels of cysteinyl leukotrienes(CysLTs) and 5-lipoxygenase activating protein(FLAP) mRNA in children with asthma and their clinical significance.Methods Forty children(aged 5 years or younger) with asthma were divided into mild, moderate, severe and critical groups according to the severity of asthma.And 10 healthy children were selected as control group.All children with asthma were randomly divided into conventional treatment group(n=20) and leukotrienes(LTs) antagonist group( n=20) .The peripheral blood samples were collected within 24 hours of admission,10 days,3 months,1 year and 2 years after treatment,respectively,for determining the level of CysLTs and the relative value of FLAP mRNA/β-action mRNA,and the severity of asthma and efficacy were recorded.Results Children with asthma obtained a higher level of CysLTs and higher relative value of FLAP mRNA/β-action mRNA on admission compared to the controls(P〈0.05),and the level of CysLTs and the relative value of FLAP mRNA/β-action mRNA positively correlated with the severity of asthma(P〈0.05).Ten days,3 months,1 year and 2 years after treatment,the severity of asthma in the LTs antagonist group was milder compared to that in the conventional treatment group,with no significant difference(P〉0.05),but the efficacy of LTs antagonist group was superior to that of conventional treatment group(P〈0.05).The levels of CysLTs and the relative values of FLAP mRNA/β-action mRNA in the LTs antagonist group were significantly lower than those in the conventional treatment group at all time points after treatment(P〈0.05).Conclusion The levels of CysLTs and FLAP mRNA both positively correlate with the severity of asthma,and CysLTs may become an important index for the researches on pathogenic mechanism and medication of asthma.LTs antagonist combined with ICS has a synergistic effect on children with asthma,thus effectively controling the levels of CysLTs and FLAP mRNA.
出处 《广西医学》 CAS 2015年第8期1121-1124,共4页 Guangxi Medical Journal
基金 广东省东莞市科技计划医疗卫生类科研项目(201210515024069)
关键词 哮喘 半胱氨酰白三烯 5-脂氧合酶激活蛋白 白三烯拮抗剂 疗效 儿童 Asthma Cysteinyl leukotrienes 5-lipoxygenase activating protein Leukotrienes antagonist Efficacy Children
  • 相关文献

参考文献10

二级参考文献31

  • 1吕刚,韩笑,张秀娟,徐卫平,杜培革.半胱氨酰白三烯受体的研究进展[J].吉林医药学院学报,2008,29(3):164-167. 被引量:4
  • 2Oh JW, Shin SA, Lee HB. Urine leukotriene E and eosinophil cationic protein in nasopharyngeal aspiration from young wheezy children [J]. Pediatr Allergy Immunol, 2005,16(5) :416-421.
  • 3Welliver RC. Therapy for bronchiolitis : help wanted [J ]. J Pediatr, 1997,130(2) : 170-172.
  • 4Piedimonte G, Simoes EA. Respiratory syncytial virus and subsequent asthma: one step closer to unravelling the Gordian knot? [J].Eur Respir J,2002,20 (3):515- 517.
  • 5Ngamphaiboon J. Montelukast in general pediatric practices[J].J Med Assoc Thai,2005,88(4):348-351.
  • 6Bonville CA, Rosenberg HF, Domachowske JB. Ribavirin and cysteinyl leukotriene-1 receptor blockade as treatment for severe bronchiolitis[J]. Antiviral Res, 2006,69 (2) : 53-59.
  • 7Graeme PC,Daniel KC,Kay h,et al.Effects of montelukast on surrogate inflammatory markers in corticosteroid-treated patients with asthma[J].Am J Respir Crit Care Med,2003,16(7):1232.
  • 8Jacobsen JR. Third - generation long - acting 13 ( 2 ) - adrenoceptor agonists:medicinal chemistry strategies employed in the identification of once - daily inhaled 13 ( 2 ) - adrenoceptor agonists [ J ]. Future Med Chem,2011 ;3 : 1607 - 1622.
  • 9Procopiou PA, Barrett V J, Ford A J, et al. The discovery of long - acting saligenin β (2) adrenergic receptor agonists incorporating a urea group [ J ]. Bioorg Med Chem, 2011 ; 19:6026 - 6032.
  • 10Bateman ED, Rabe KF, Calverley PM, et al. Roflumilast with long - acting 132 - agonists for COPD : influence of exacerbation history [ J]. Eur Respir J,2011 ;38:553 - 560.

共引文献2600

同被引文献49

引证文献4

二级引证文献55

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部